Table 3.

Effects on VEGF-mediated angiogenesis of continuously infused dalteparin administered subcutaneously at different doses for 14 consecutive days

Dalteparin IU/kg/day	Angiogenesis variables
	VA1	MVL	TMVL
Vehicle control (n = 12)	11.72 ± 2.66 (100)	0.901 ± 0.100 (100)	10.56 ± 2.40 (100)
27 (n = 12)	16.07 ± 2.67 (137)	1.126 ± 0.072** (125)	18.09 ± 3.00** (171)
80 (n = 11)	16.89 ± 3.82 (144)	1.064 ± 0.107 (118)	17.26 ± 3.90* (163)
240 (n = 9)	13.51 ± 1.93 (115)	0.872 ± 0.076*** (97)	11.78 ± 1.68 (112)

Values within parenthesis are percent of control.

¹VA, a measurement of microvessel spatial extension; MVL, a composite measurement of microvessel density; TMVL = (VA × MVL).

^*p ≤ 0.10,

^**p ≤ 0.05 compared with vehicle (0.9% NaCl) control;

^***p ≤ 0.05 compared with the low dose of 27 IU/kg/day. Data shown are mean ± SEM. n = number of animals.

On Day 10 of the 14-day treatment, one animal in the 80 IU/kg/day group and three animals in the 240 IU/kg/day group developed s.c. blood-streaked liquid accumulation at the site of the osmotic infusion pump and were therefore sacrificed. These animals are excluded from the analysis.